ArticleVirchows Archiv : an international journal of pathology2026
The role of external quality assessment in detecting immunohistochemical analyses with inferior performance: focus on the anti-ER SP1 clone.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Oestrogen receptor (ER) expression is a prognostic and predictive marker in invasive breast cancer. Varying staining quality of immunohistochemical assays may potentially lead to misclassifications of cancers, thereby impacting therapy decisions and compromising patient safety. A recent recall notice for the anti-ER SP1 clone raised awareness about reduced staining intensity by faulty batches. Inconsistencies in antibody dilution by the vendor caused inferior SP1 performance. We analysed publicly available data from external quality assessment (EQA) programmes for ER immunohistochemistry (IHC), comprising NordiQC and the Belgian national public health institute Sciensano. IHC with the affected SP1 batches did not meet the descriptive lower limit of detection, resulting in interlaboratory performance variations and decreased EQA pass rates. We conclude that EQAs can retrospectively reveal global inferior performance of a particular clone. Additionally, the recent anti-ER SP1 clone issues highlight the importance of the use of on-slide positive controls.
Indexed as
Identifiers
42068353What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.